medigraphic.com

2015, Number S2

<< Back Next >>

Rev Mex Anest 2015; 38 (S2)

Reversal of anticoagulation

Carrillo-Esper R, Villagrana-Rodríguez MA, Garrido-Aguirre E

Language: Spanish
References: 12
Page: 402-405
PDF size: 164.32 Kb.


ABSTRACT

The use of anticoagulation is common practice in medicine today and therein lies its importance. This paper describes the different therapeutic strategies for the treatment of excess anticoagulation, because depending on the agent used, a special agent for the reversal is needed. The introduction of new oral anticoagulants promotes the study of new agents for the treatment of complications resulting therefrom; for the reversal, these agents are already in the last phase of clinical trials before proposed as a treatment option. The use of new strategies to reverse excessive anticoagulation can be done more safely by using new concentrates of clotting factors, which have well established precise indications and dosage.


REFERENCES

  1. Monagle P, Chalmers E, Chan A, DeVeber G, Kirkham F, Massicotte P, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008;133:887S-968S.

  2. Watson HG, Baglin T, Laidlaw SL, Makris M, Preston FE. A comparison of the efficacy and rate of response to oral and intravenous Vitamin K in reversal of overanticoagulation with warfarin. Br J Haematol. 2001;115:145-149.

  3. Dentali F, Ageno W, Crowther M. Treatment of coumarin-associated coagulopathy: a systematic review and proposed treatment algorithms. J Thromb Haemost. 2006;4:1853-1863.

  4. Diug B, Evans S, Lowthian J, Maxwell E, Dooley M, Street A, et al. The unrecognized psychosocial factors contributing to bleeding risk in warfarin therapy. Stroke. 2011;42:2866-2871.

  5. Kucher N, Connolly S, Beckman JA, Cheng LH, Tsilimingras KV, Fanikos J, et al. International normalized ratio increase before warfarin-associated hemorrhage: brief and subtle. Arch Intern Med. 2004;164:2176-2179.

  6. Schulman S. Clinical practice. Care of patients receiving long-term anticoagulant therapy. N Engl J Med. 2003;349:675-683.

  7. O’Shaughnessy DF, Atterbury C, Bolton-Maggs P, Murphy M, Thomas D, Yates S, et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol. 2004;126:11-28.

  8. Crowther MA, Douketis JD, Schnurr T, Steidi L, Mera V, Ultori C, et al. Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial. Ann Intern Med. 2002;137:251-254.

  9. Holland L, Warkentin TE, Refaai M, Crowther MA, Johnston MA, Sarode R. Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose. Transfusion. 2009;49:1171-1177.

  10. Turagam MK, Velagapudi P, Bongu NR, Kocheril AG. Novel anticoagulants vs. warfarin for stroke prevention in atrial fibrillation. Cardiovasc Hematol Disord Drug Targets. 2014;14:79-86.

  11. Lu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ, Abe K, Lee G, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med. 2013;19:446-451.

  12. Liotta EM, Levasseur-Franklin KE, Naidech AM. Reversión de la novela orales anticoagulantes dabigatrán, rivaroxabán y apixabán. Curr Opin Crit Care. 2015;21:127-33.




2020     |     www.medigraphic.com